A phase I/IIa first-in-human study of PM1003 (anti-PD-L1 x 4-1BB bispecific antibody) in patients with advanced solid tumors

被引：0

作者：

Xue, J. ^{[1
]}

Sun, Y. ^{[2
]}

Li, D. ^{[3
]}

Guo, Y. ^{[1
]}

机构：

[1] Shanghai East Hosp, Tongji Univ, Sch Med, Med Oncol, Shanghai, Peoples R China

[2] Shandong First Med Univ, Phase I Clin Study Dept, Canc Hosp, Jinan, Peoples R China

[3] Shandong First Med Univ, Med Oncol, Canc Hosp, Jinan, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2175

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1036P

引用

页码：S629 / S629

页数：1

共 50 条

[41] A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors [J].

Callahan, Margaret K. ;

Ott, Patrick Alexander ;

Odunsi, Kunle ;

Bertolini, Staphane V. ;

Pan, Linda S. ;

Venhaus, Ralph Rudolph ;

Karakunnel, Joyson Joseph ;

Hodi, F. Stephen ;

Wolchok, Jedd D. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[42] First-in- class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study [J].

Bai, X. ;

Chen, Y. ;

Liang, X. ;

Wang, H. ;

Sun, Y. ;

Chu, Q. ;

Pan, Y. ;

Cui, J. ;

Fang, J. ;

Zhang, W. ;

Xu, Q. ;

Zhang, J. ;

Liu, X. ;

Dai, G. ;

Kang, L. ;

Li, N. ;

Fang, M. ;

Zhou, H. ;

Liang, T. .

ANNALS OF ONCOLOGY, 2024, 35 (07) :681-682

[43] First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors [J].

Shitara, Kohei ;

Uehai, Satoshi ;

Shichino, Shigeyuki ;

Aoki, Hiroyasu ;

Ogiwara, Haru ;

Nakatsura, Tetsuya ;

Suzuki, Toshihiro ;

Shimomura, Manami ;

Yoshikawa, Toshiaki ;

Shoda, Kayoko ;

Kitano, Shigehisa ;

Yamashita, Makiko ;

Nakayama, Takayuki ;

Sato, Akihiro ;

Kuroda, Sakiko ;

Wakabayashi, Masashi ;

Nomura, Shogo ;

Yokochi, Shoji ;

Ito, Satoru ;

Matsushima, Kouji ;

Doi, Toshihiko .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 :195

[44] Phase I study of the investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific SGN-BB228 (PF-08046049) in advanced melanoma and other solid tumors [J].

Dummer, R. ;

Daud, A. ;

Eigentler, T. K. ;

Evans, T. R. J. ;

Henry, J. ;

Hodi, F. S. ;

Miller, W. H. ;

Robert, C. ;

Saibil, S. ;

Tachiki, L. ;

Nayeri, M. ;

Xing, B. ;

Mehnert, J. M. .

ANNALS OF ONCOLOGY, 2024, 35 :S709-S709

[45] Phase I safety and pharmacokinetic study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in Japanese patients with advanced solid tumors. [J].

Shimizu, Toshio ;

Nakajima, Takako Eguchi ;

Lu, Ni ;

Xue, Shilin ;

Xu, Wenlian ;

Fu, Meng ;

Cao, Walt ;

Lu, Haolan ;

Liu, David ;

Dong, RuiPing ;

Wang, Xiaoxiao ;

Wang, Pilin ;

Zhu, Danming ;

Xu, Ting ;

Gong, John .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[46] Phase I/II safety and preliminary efficacy of PM1022, a bispecific antibody targeting PD-L1 and TIGIT, in patients with advanced solid tumors [J].

Xue, Junli ;

Zhang, Yan ;

Hu, Xudong ;

Zhao, Wei ;

Sun, Yuping ;

Li, Qun ;

Jin, Xiaoying ;

Xue, Liqiong ;

Ge, Xiaoxiao ;

Lin, Fengjuan ;

Tang, Wenbo ;

Zhou, Jiuli ;

Guo, Ye .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[47] Phase 1 study of SGN-BB228, an investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific, in patients with advanced melanoma and other solid tumors (SGNBB228-001). [J].

Henry, Jason Timothy ;

Mehnert, Janice M. ;

Rudnicki, Erika ;

Pinelli, Juan ;

Daud, Adil .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

[48] A Phase 1 first-in-human study of MEDI0680, an anti-PD-1 monoclonal antibody (mAb) in adult patients (pts) with advanced tumors [J].

Naing, A. ;

Goel, S. ;

Curti, B. ;

Weise, A. ;

Eder, J. P. ;

Marshall, S. ;

Morehouse, C. ;

Li, X. ;

Karakunnel, J. J. ;

Infante, J. .

ANNALS OF ONCOLOGY, 2016, 27

[49] BATF3 DENDRITIC CELLS AND 4-1BB/4-1BB LIGAND AXIS ARE REQUIRED AT THE EFFECTOR PHASE WITHIN THE TUMOR MICROENVIRONMENT FOR ANTI-PD-L1 EFFICACY [J].

Ziblat, Andrea ;

Horton, Brendan ;

Higgs, Emily ;

Hatogai, Ken ;

Gajewski, Thomas .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 :A354-A354

[50] Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naive advanced solid tumors [J].

Carneiro, Benedito A. ;

Safran, Howard ;

Beck, J. Thaddeus Thaddeus ;

Hamid, Omid ;

Spira, Alexander I. ;

Savvides, Panos ;

Gutierrez, Martin ;

Zhao, Yujie ;

Abbruzzese, James L. ;

Ward, Jeffrey P. ;

Weroha, Saravut John ;

Harris, Loleta D. ;

Kent, Sean ;

Pierceall, William ;

Skoura, Athanasia ;

Zheng, Jenny ;

Kern, Kenneth Alan ;

Thomas, Jacob Stephen ;

Santana-Davila, Rafael .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →